.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ04_Albiglutide.Albiglutide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ04_Albiglutide.Albiglutide| name: | Albiglutide |
| ATC code: | A10BJ04 | route: | subcutaneous |
| n-compartments | 2 |
Albiglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus to improve glycemic control. It is administered as a once-weekly subcutaneous injection. Albiglutide was approved for use in several countries but was withdrawn from the market in 2018 for commercial reasons, not safety concerns.
Pharmacokinetic parameters following single subcutaneous administration in adults with type 2 diabetes.
Seino, Y, et al., & Stewart, MW (2009). Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Current medical research and opinion 25(12) 3049–3057. DOI:10.1185/03007990903372999 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19863477